No connection

Search Results

Corporate Score 42 Bullish

Celcuity Shares Climb Following Bullish Analyst Initiation and Pending FDA Decision

Apr 27, 2026 22:38 UTC
CELC
Short term

Celcuity (CELC) saw a share price increase of nearly 4% after Citizens analyst Silvan Turkcan initiated coverage with a 'market outperform' rating. The positive sentiment is driven by the upcoming FDA review of the company's lead oncology candidate, gedatolisib.

  • Shares rose nearly 4% on Monday
  • Analyst price target set at $150
  • FDA decision expected within two months
  • Lead candidate gedatolisib targets advanced breast cancer
  • Potential for future label expansion into other cancers

Celcuity (NASDAQ: CELC) experienced a positive shift in investor sentiment on Monday, with shares rising nearly 4% following the initiation of coverage by analyst Silvan Turkcan of Citizens. The rally is centered on the potential approval of gedatolisib, an investigational drug designed to treat advanced breast cancer. The company is currently in a critical window, as the Food and Drug Administration (FDA) is expected to complete its review of the New Drug Application (NDA) in less than two months. Turkcan assigned a 'market outperform' rating to the clinical-stage biotech firm, setting a price target of $150 per share. This target represents an approximate 20% upside from the stock's most recent closing price, positioning it as one of the more optimistic valuations among analysts covering the company. Beyond the immediate breast cancer application, analysis suggests that gedatolisib could eventually be approved for other oncology indications. Such an expansion would significantly increase the drug's market value and the company's overall valuation, potentially transforming Celcuity from a clinical-stage entity into a commercial-stage pharmaceutical player.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 32

TPG Secures Majority Stake in Japanese Logistics Portfolio from ESR

Apr 28, 03:15

Score 42 Bullish

Teva Pharmaceutical Eyes Long-Term Growth Amid Strategic Pivot to Proprietary Drugs

Apr 28, 02:03

Score 35

Chinese VC Firms Adopt Parallel Structures to Attract US Capital

Apr 28, 01:53

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile